(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 April 2022 (28.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/082306 A1

(51) International Patent Classification:
A61K 31/4439 (2006.01) *A61P 29/00* (2006.01)
A61K 31/416 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/CA2021/051475

(22) International Filing Date:
20 October 2021 (20.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/093,970 20 October 2020 (20.10.2020) US

(71) Applicant: **PACYLEX PHARMACEUTICALS INC.** [CA/CA]; 400 3rd Avenue SW, Suite 7000, Calgary, Alberta T2P 4H2 (CA).

(72) Inventors: **BERTHIAUME, Luc G.**; 10061, 90 Avenue NW, Edmonton, Alberta T6E 4X2 (CA). **BEAUCHAMP, Erwan**; 7711, 79 Avenue, Edmonton, Alberta T6C 0P5 (CA).

(74) Agent: **VICKERS, Mark F.** et al.; Borden Ladner Gervais LLP, 100 Queen Street, Suite 1300, Ottawa, Ontario K1P 1J9 (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2022/082306 A1

(54) Title: USE OF N-MYRISTOYL TRANSFERASE (NMT) INHIBITORS IN THE TREATMENT OF CANCER, AUTOIMMUNE DISORDERS, AND INFLAMMATORY DISORDERS

(57) Abstract: The use of N-myristoyl- transferase (NMT) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders is disclosed. With respect to cancer, the preferred cancer to be treated is B-cell lymphoma, and the NMT used is PCLX-001 (DDD86481, CAS RN 1215011-08-7). Preferred NMT inhibitors for the treatment of autoimmune and inflammatory disorders include the aforementioned PCLX-001, PCLX-002 (DDD85646, CAS RN 1215010-55-10), and IMP-1088 (CAS RN 2059148-82-0), and the disorders to be treated include rheumatoid arthritis, asthma, gastritis, colitis, and other digestive and respiratory ailments.